{"id":"W4386151402","doi":"10.1002/ejhf.2990","title":"Baseline Characteristics of Patients Enrolled in the EMPACT-MI Trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; Women's College Hospital; University of Toronto","funders":"Janssen Pharmaceuticals; St. Jude Medical; HLS Therapeutics; Daiichi Sankyo Europe; Servier; Assistance publique-Hôpitaux de Paris; Agency for Healthcare Research and Quality; Vifor Pharma; Pfizer; Moderna; Idorsia Pharmaceuticals; Impulse Dynamics; Medicines Company; Regado Biosciences; Belvoir Media Group; Novo Nordisk; MyoKardia; AstraZeneca; Amarin Corporation; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Regeneron Pharmaceuticals; Duke Clinical Research Institute; Eisai; Brigham and Women's Hospital; Boston VA Research Institute; Boston Scientific Corporation; Eli Lilly and Company; Cleveland Clinic; Bristol-Myers Squibb; CSL Behring; British Heart Foundation; Amgen; Sanofi; American Heart Association","keywords":"Medicine; Empagliflozin; Myocardial infarction; Internal medicine; Heart failure; Cardiology; Ejection fraction; Population; Interquartile range; Diabetes mellitus; Type 2 diabetes; Placebo","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001561251,0.0004456981,0.0009751149,0.0003741796,0.0005337364,0.0009118606,0.0003263851,0.0007971628,0.005441814],"category_scores_gemma":[0.002526346,0.0002478179,0.0008357498,0.0008089623,0.0002844624,0.0008928618,0.000326484,0.001267996,0.0007436277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002982347,"about_ca_system_score_gemma":0.0004771529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005293102,"about_ca_topic_score_gemma":0.0006877299,"domain_scores_codex":[0.9991527,0.0001985858,0.000133808,0.0002144728,0.0001628772,0.0001376856],"domain_scores_gemma":[0.9992537,0.0001571321,0.0002504526,0.00006013149,0.00007788237,0.0002006173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06614124,0.00314423,0.881975,0.0006428913,0.002661093,0.0005934926,0.0002033572,0.0008424571,0.002547058,0.0006682147,0.01358152,0.0269994],"study_design_scores_gemma":[0.01356362,0.008312614,0.9650985,0.000164124,0.0008835981,0.0009965941,0.0002066239,0.001202893,0.0003963437,0.0009361301,0.008170727,0.00006815422],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9661319,0.005725932,0.0009460226,0.001053628,0.0002626111,0.001095775,0.01545962,0.00003206487,0.00929254],"genre_scores_gemma":[0.9792955,0.0008632049,0.000345435,0.001341986,0.0002817398,0.001947246,0.01349769,0.00001425964,0.002412966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005441814,"threshold_uncertainty_score":0.01820469,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01711299188517357,"score_gpt":0.2542449277176738,"score_spread":0.2371319358325003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}